FNArena Windows
Introduction to FNArena Windows
FNArena Windows offers subscribers the option to investigate ASX-listed stocks against their peers. FNArena developed its own sector methodology which in our view overcomes many flaws and disadvantages connected with GICS sectors. Our system starts with three broad sector labels: COMMODITIES, FINANCIAL SERVICES and INDUSTRIALS. From here onwards subscribers can explore further through gradually narrowing branches. This is not investment advice, but simply another window on the Australian Stock Exchange to provide better insight and to assist FNArena subscribers while conducting their own market analysis.
| ASX CODE | LAST PRICE | % MOVE | 52WK HIGH | 52WK LOW | P/E | CONSENSUS TARGET | UPSIDE/DOWNSIDE |
|---|---|---|---|---|---|---|---|
| 1AD | $0.01 | 0.00% | $0.02 | $0.00 |
|
||
| ACR | $0.02 | 0.00% | $0.03 | $0.01 |
|
||
| ACW | $0.04 | 0.00% | $0.07 | $0.02 |
|
||
| ADO | $0.01 | 0.00% | $0.03 | $0.01 |
|
||
| AFP | $3.23 |
|
$3.37 | $2.20 |
|
||
| AGN | $0.28 | 0.00% | $0.89 | $0.19 |
|
||
| ARX | $0.70 |
|
$0.80 | $0.35 | 141.7 |
$0.82 |
|
| AVH | $1.09 |
|
$3.38 | $1.00 |
$1.275 |
|
|
| BIO | $0.43 |
|
$0.72 | $0.39 | 28.7 |
$1.00 |
|
| BOT | $0.12 | 0.00% | $0.54 | $0.10 |
|
||
| COV | $0.57 |
|
$0.90 | $0.31 |
|
||
| CSL | $151.91 |
|
$275.79 | $150.21 | 16.0 |
$207.477 |
|
| CUV | $10.72 |
|
$14.00 | $9.41 | 15.4 |
$16.50 |
|
| DXB | $0.51 |
|
$0.79 | $0.34 |
|
||
| GSS | $0.13 |
|
$0.69 | $0.13 |
$0.55 |
|
|
| IDT | $0.05 | 0.00% | $0.12 | $0.05 |
|
||
| ILA | $0.40 |
|
$0.63 | $0.12 |
|
||
| IMM | $0.37 | 0.00% | $0.47 | $0.22 |
$1.075 |
|
|
| IMU | $0.26 | 0.00% | $0.46 | $0.01 |
$0.82 |
|
|
| IVX | $0.08 | 0.00% | $0.20 | $0.08 |
|
||
| LGP | $0.12 | 0.00% | $0.15 | $0.10 |
|
||
| MAP | $0.09 | 0.00% | $0.27 | $0.07 |
$0.21 |
|
|
| MSB | $2.47 |
|
$3.31 | $1.52 | -86.1 |
$4.45 |
|
| MVP | $0.46 | 0.00% | $0.94 | $0.42 |
$0.84 |
|
|
| MYX | $2.71 |
|
$7.31 | $2.60 |
|
||
| NEU | $13.30 |
|
$22.99 | $8.61 | 98.7 |
$24.567 |
|
| NUZ | $0.10 | 0.00% | $0.19 | $0.08 |
$0.28 |
|
|
| OCC | $0.93 |
|
$1.70 | $0.86 |
|
||
| OSL | $0.69 |
|
$2.09 | $0.00 |
|
||
| PAR | $0.31 | 0.00% | $0.66 | $0.26 |
$0.65 |
|
|
| PER | $0.01 | 0.00% | $0.02 | $0.01 |
|
||
| PNV | $0.95 |
|
$2.07 | $0.92 | 41.3 |
$1.977 |
|
| PYC | $1.49 |
|
$1.76 | $0.85 |
$2.30 |
|
|
| RAC | $2.28 |
|
$4.90 | $0.92 |
|
||
| RCE | $0.58 |
|
$0.73 | $0.28 |
|
||
| SNT | $0.03 | 0.00% | $0.10 | $0.02 |
$0.06 |
|
|
| SPL | $0.48 |
|
$0.50 | $0.08 |
|
||
| TLX | $9.24 |
|
$31.97 | $9.59 | -558.0 |
$27.24 |
|
| TRP | $0.19 | 0.00% | $0.48 | $0.17 |
|
||
| VIT | $0.05 | 0.00% | $0.14 | $0.05 |
|
||
| ZNO | $0.07 | 0.00% | $0.18 | $0.03 |
|
0.94% Previous Stories
Dr Boreham’s Crucible: Invion
May 13 2024
As per the New Criterion’s Tim Boreham, Invion is an old company on a new mission
Dr Boreham’s Crucible: Race Oncology
Apr 09 2024
Race Oncology tells a story all too familiar among developing Aussie biotechs, Tim Boreham reports
The Power Of New Weight-Loss Drugs
Apr 03 2024
GLP-1s offer far more across the healthcare sector than just weight-loss, with far-reaching societal implications, explains T. Rowe Price’s Nabil Hanano
Dr Boreham’s Crucible: Neuren Pharmaceuticals
Mar 11 2024
Tim Boreham reports Neuren Pharmaceuticals has suffered from accusations from an activist shorter which others have debunked
Spotlight On ASX-Listed Cannabis Companies
Jan 31 2024
Some cannabis gems are sprouting in the ASX weed patch, but they are hard to find in the haze of hype, Tim Boreham, Editor, The New Criterion reports
Transformational Trial Results For Neuren Pharmaceuticals
Dec 20 2023
Brokers raise valuations for Neuren Pharmaceuticals following positive Phase 2 clinical trial results
Dr Boreham’s Crucible: Imugene
Dec 11 2023
Tim Boreham highlights the prospects for cancer treatment biotech Imugene
Dr Boreham’s Crucible: PYC Therapeutics
Nov 22 2023
Tim Boreham highlights how PYC Therapeutics’ gene therapy can address a plethora of genetic afflictions
Dr Boreham’s Crucible: Paradigm Biopharmaceuticals
Nov 06 2023
Tim Boreham highlights the success of Paradigm Biopharmaceuticals’ joint pain drug ahead of a capital raising
Dr Boreham’s Crucible: Argenica Therapeutics
Sep 28 2023
Argenica Therapeutics is aiming for a substantial slice of the stroke market, expected to be worth some US$180bn a year by 2030
Latest News
| 1 |
FNArena Corporate Results Monitor – 12-02-20262:01 PM - Australia |
| 2 |
Australian Broker Call *Extra* Edition – Feb 12, 20261:26 PM - Daily Market Reports |
| 3 |
The Short Report – 12 Feb 202611:00 AM - Weekly Reports |
| 4 |
A Healthy Correction Underway10:30 AM - International |
| 5 |
AI Fears Overwhelm REA’s Operational Resilience10:00 AM - Australia |